Icosavax to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023
Icosavax to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023
SEATTLE, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in the Cantor Fitzgerald Global Healthcare Conference 2023, taking place from September 26-28, 2023 in New York City.
西雅图，9月2023年10月19日(环球网)--生物制药公司ICosavax，Inc.(纳斯达克股票代码：ICVX)今天宣布，该公司将参加2023年9月26日至28日在纽约市举行的坎托·菲茨杰拉德全球医疗大会。该公司利用其创新的病毒样颗粒(VLP)平台技术开发针对传染病的疫苗，最初专注于危及生命的呼吸系统疾病，并着眼于为老年人创造泛呼吸道疫苗。
Cantor Fitzgerald Global Healthcare Conference 2023
康托·菲茨杰拉德2023年全球医疗会议
- Adam Simpson, Chief Executive Officer of Icosavax, will participate in a fireside chat in New York City on Tuesday, September 26 at 8:45 am ET in Track 3
- ICosavax首席执行官亚当·辛普森将于美国东部时间9月26日星期二上午8：45参加纽约市3号赛道的炉边聊天
Interested parties can register for and access the live webcast for this conference by visiting the "Events" section of the Icosavax website. The webcast replay will be available after the conclusion of the presentation.
感兴趣的各方可通过访问ICosavax网站的“活动”部分注册并收看本次会议的现场网络直播。网络直播重播将在演讲结束后播出。
About Icosavax
关于ICosavax
Icosavax is a biopharmaceutical company leveraging its innovative VLP platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision for combination and pan-respiratory vaccines. Icosavax's VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax's lead program is a combination vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), and its pipeline includes additional programs in influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases. Icosavax is located in Seattle.
ICosavax是一家生物制药公司，利用其创新的VLP平台技术开发针对传染病的疫苗，最初专注于威胁生命的呼吸道疾病，并展望组合和泛呼吸道疫苗。ICosavax的VLP平台技术旨在实现复杂病毒抗原的多价、基于颗粒的展示，该公司相信这将对目标特定病毒提供广泛、强大和持久的保护。ICosavax的主导计划是针对呼吸道合胞病毒(RSV)和人类偏肺病毒(HMPV)的一种组合候选疫苗，其正在筹备中的计划包括针对流感和严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的额外计划。ICosavax成立于2017年，旨在推进华盛顿大学蛋白质设计研究所的突破性VLP技术，目标是发现、开发传染病疫苗并将其商业化。Icoavax公司位于西雅图。
For more information, visit .
有关更多信息，请访问。
Media Contact:
Jessica Yingling, Ph.D.,
Little Dog Communications Inc.
jessica@litldog.com
858.344.8091
媒体联系人：
Jessica Yingling，博士，
小狗通信公司。
邮箱：jessica@litldog.com
858.344.8091
Investor Contact:
Laurence Watts
Gilmartin Group, LLC
laurence@gilmartinir.com
619.916.7620
投资者联系方式：
劳伦斯·瓦茨
Gilmartin Group，LLC
邮箱：laurence@gilmartinir.com
619.916.7620